Our fourth quarter edition features leading insights from key opinion leaders with findings specific to data integration and the industry today.Download Issue
The potential applications for this vast quantity and variety of data are nearly endless.
Numerous drugs formulated as amorphous solid dispersions have been successfully commercialized.
Brammer’s vision is to be the leading CDMO for viral vector supply to cell and gene therapy innovators.
Technology transfer should result in the transfer of product and process knowledge into a new phase of the life cycle.
We offer a turnkey solution by sourcing equipment that meets production line requirements.
An oligo drug manufacturing facility incorporates aspects of small-molecule and biologic drug facilities.
The FDA issued new guidances regarding enforcement of the DSCSA's track and trace mandate.
Companies that apply the data will have a competitive advantage in drug discovery and development.
To achieve cohesive data integration in drug manufacturing, systems must be aligned.
The emphasis on serialization is a tangible move toward making post-market data mining more robust.
Pharmaceutical companies should prepare for Brexit by mitigating their supply chain risks.
Computer-based approaches are essential to enable systematic drug repositioning efforts.
Continued investment in innovations that address the needs of current and next-generation therapies is essential.
Collaborating with an embedded organization with an integrated, global network can facilitate access to growing markets.
Servier’s InnoPreP™ technology offering appeals to mid-size pharmas who need to quickly move their project into clinical studies .
siRNA joins the other nucleic acid–based drugs entering the marketplace for the treatment of rare diseases.
Given the amount of Chinese capital and the growing interest in the segment, the market feels unlimited.
Industry leaders discuss recent technological innovations.
Industry leaders discuss forthcoming technological innovations.